EP2004235B1 - Composition for cosmetic or pharmaceutical-dermatological use - Google Patents

Composition for cosmetic or pharmaceutical-dermatological use Download PDF

Info

Publication number
EP2004235B1
EP2004235B1 EP07733952A EP07733952A EP2004235B1 EP 2004235 B1 EP2004235 B1 EP 2004235B1 EP 07733952 A EP07733952 A EP 07733952A EP 07733952 A EP07733952 A EP 07733952A EP 2004235 B1 EP2004235 B1 EP 2004235B1
Authority
EP
European Patent Office
Prior art keywords
composition
curcumin
zinc
derivatives
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP07733952A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2004235A2 (en
Inventor
Laura Martelli
Mario Martelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scharper Therapeutics Srl
Original Assignee
Pharmaland SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaland SA filed Critical Pharmaland SA
Priority to PL07733952T priority Critical patent/PL2004235T3/pl
Publication of EP2004235A2 publication Critical patent/EP2004235A2/en
Application granted granted Critical
Publication of EP2004235B1 publication Critical patent/EP2004235B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to compositions for cosmetic or pharmaceutical-dermatological use, suitable for maintaining skin cells at, or helping to restore skin cells to, their basal physiological state, enabling them to effect a regeneration of the skin.
  • compositions whose aim is precisely to resist the appearance of the aforesaid ageing phenomena, though their level of effectiveness is not currently such that the aforementioned need is satisfied.
  • composition of the present invention comprising:
  • compositions are able to restore skin cells to their basal physiological state, enabling them to effect a regeneration of the dermis and epidermis as demonstrated by experiments undertaken at both the cellular and clinical levels.
  • the present invention therefore provides formulations for cosmetic use comprising the aforesaid compositions, in particular for preventing wrinkle formation and able to prevent elastosis.
  • the present invention also provides compositions in the form of a medicament for dermatological use, particularly for treating skin pathologies where it is essential to block the inflammatory process, by modulating the calcium and free radical channels caused by oxidative processes, in order to achieve skin regeneration.
  • Curcumin characterized by the following formula:
  • Curcuma longa or Curcuma xanthorrhiza is a natural extract of Curcuma longa or Curcuma xanthorrhiza, known for its generic antibacterial, antifungal and antiparasitic activity ( Ars Pharmaceutica 2000, 41(3), 307-321 ).
  • Curcumin and curcuminoids also behave as muscle relaxants ( Life Science 2005, 76, 3089 ), inhibit the activation of nuclear factor NFkB where the paths causing and sustaining inflammation converge ( J. Biol. Chem. 1995, 270, 24995 ), and are able to inactivate ROS (Reactive Oxygen Species) particularly superoxide ions ( Ann. Chim. 2002, 92, 281 ).
  • ROS Reactive Oxygen Species
  • Curcumin is preferably present in the composition of the invention at concentrations between 0.0005% and 10% on the total composition weight.
  • the phosphosaccharide used in the composition of the present invention is preferably chosen from the group consisting of mannose, glucose, galactose and fructose phosphates.
  • Fructose 1-6 diphosphate (abbreviated to FDP hereinafter) is particularly preferred.
  • FDP The stated phosphosaccharides, and in particular FDP, are metabolites of glycolysis able to provide easily available energy for cell biochemistry. FDP also possesses prostaglandin E2 (PGE2) and cyclooxygenase inhibitory activity, and is able to preserve the antioxidative capacity of keratinocytes irradiated with ultraviolet B radiation ( British J. Pharmacol. 2002, 137, 497 ). Furthermore, in the presence of sodium and magnesium ions, FDP is accredited with protecting neurones from ischemic attack ( Yao Xue Bao. 2003, 38, 325 ) and cells from various noxae, and facilitating metabolic recovery in ischemic tissue even in conditions of hypoxia ( Am. J. Physiol. 1994, 267, H 2325 ).
  • FDP is used mainly for ischemic myocarditis where it interacts with the plasma membrane and stimulates enrichment of the energy-rich intracellular phosphate pool, including 2-3 diphosphogluconate (Esafosfina - information from Biomedica Foscama).
  • Curcumin and phosphosaccharides chosen from the group specified above have surprisingly shown a good synergistic effect when used in combination, enabling skin cells to recover as much as possible their basal level of efficiency.
  • phosphosaccharide is used in concentrations between 0.001% and 25% by weight on the total composition weight.
  • compositions of the present invention contain the salts or biologically acceptable oxides of a metal able to form, with at least one of the aforesaid essential compounds, coordination compounds or associations which enhance their activity.
  • the metals contained in the salts or oxides possibly present are chosen from calcium, magnesium, copper, bismuth, zinc, aluminium, manganese, antimony, tin, gold, silver, chromium, cobalt, vanadium or titanium.
  • compositions of the present invention contain oxides or salts of the aforesaid metals able to completely or partially complex curcumin.
  • compositions of the present invention contain only complexed curcumin.
  • compositions of the present invention comprise an association of curcumin and complexed curcumin.
  • Formation of the zinc-curcumin complex can be achieved by dissolving the zinc salt in a hydroalcoholic solution to which curcumin is added in a 1:1 molar ratio.
  • compositions useful for sustaining and directing cellular activity when the recovery of basal-physiological conditions indicates full cellular activity has been restored.
  • composition of the present invention will be enriched with one or more compounds chosen from the group consisting of fruit acids, ( ⁇ -hydroxy acids), glucosaminoglycans, urea, urea in protein mixtures, flavones, flavonoids, terpenes, diterpenes, vaseline, saturated and unsaturated fatty acids, lipids, phospholipids, coumarin and derivates, proteins, protides, amino acids, vitamins, in particular D and H group, ceramides, sphingosines, boswellic acids and derivatives, in particular those characterized by acetyl and formyl groups, starch and its derivatives, as well as monosaccharides.
  • fruit acids ⁇ -hydroxy acids
  • glucosaminoglycans glucosaminoglycans
  • urea urea in protein mixtures
  • flavones flavonoids
  • terpenes diterpenes
  • vaseline saturated and unsaturated fatty acids
  • composition of the present invention can also advantageously contain one or more compounds, in pharmaceutically compatible doses, chosen from the group consisting of pyrithione and its complex salts (in particular salts of the aforelisted metals), fumaric acid derivatives, Mahonia extracts, anthraquinone derivatives, retinoic acid derivatives, vitamin D derivatives and lactoferrins.
  • pyrithione and its complex salts in particular salts of the aforelisted metals
  • fumaric acid derivatives in particular salts of the aforelisted metals
  • Mahonia extracts anthraquinone derivatives
  • retinoic acid derivatives in vitamin D derivatives and lactoferrins.
  • lactoferrins lactoferrins
  • compositions of the present invention are given below, as well as clinical trials and in vitro cell trials which demonstrate the effectiveness of the compositions of the present invention.
  • 100 grams of a prepared product produced in accordance with the present invention comprise a lipophilic-based excipient in which the stated components are dispersed.
  • the prepared product of example 1 was used in a test conducted on a sample of twenty female volunteer patients aged between 20 and 25 years with unblemished skin, after obtaining their informed consent regarding the test method.
  • the prepared product was spread onto one arm while a placebo prepared product, formed solely of a lipophilic-based excipient, was applied to the opposite arm.
  • the entire experiment was conducted "double blind", the codes relating to the placebo and prepared product being opened only at the end of the study.
  • test results are given in table 1, as means of the values measured for each assessment parameter, together with the respective standard deviation and standard error values.
  • Oxidative stress was induced by adding a mixture of 40 mM xanthine and 2 mM hypoxanthine to the culture medium, a mixture with known ability to induce formation of Reactive Oxygen Species (ROS), agents which cause cell damage up to necrosis.
  • ROS Reactive Oxygen Species
  • the contact time between the xanthine/hypoxanthine mixture and the preparations was 2 hours, at the end of which the cells were transplanted into a fresh culture medium, i.e. containing neither the stress-inducing mixture nor the substance, then allowed to quiesce for periods of 3 or 24 hours.
  • gene expression of the prostaglandin G/H synthase and cyclooxygenase 2 (COX 2 ) enzyme was detected which is indicative of the inflammatory state induced in cells by oxidative stress.
  • the content of COX 2 mRNA in cells was then quantified by reverse transcriptase; said content was chiefly increased in cells that had borne oxidative stress the most and lowest in control cells not exposed to oxidative stress.
  • the effectiveness of the different preparations in protecting cultured human fibroblasts from oxidative stress was shown by their ability to maintain COX 2 content as low as and as close to the value found in cells not exposed to stress.
  • COX 2 normalized fluorescence units vs housekeeping gene 18s rRNA
  • Non-insulted, untreated cells 2.12 Insulted, untreated cells 12.00 curcumin 3 ⁇ M 5.00 curcumin 6 ⁇ M 4.90 Zn-curcumin complex 3 ⁇ M 4.56 FDP 5 mM 7.14 curcumin 3 ⁇ M + FDP 5 mM 4.00 curcumin 3 ⁇ M + Zn-curcumin complex 3 ⁇ M 4.00 curcumin 3 ⁇ M + Zn-curcumin complex 3 ⁇ M FDP 5 ⁇ M 3.00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
EP07733952A 2006-03-13 2007-03-13 Composition for cosmetic or pharmaceutical-dermatological use Active EP2004235B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL07733952T PL2004235T3 (pl) 2006-03-13 2007-03-13 Kompozycja do zastosowania kosmetycznego lub farmaceutyczno-dermatologicznego

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000082A ITPD20060082A1 (it) 2006-03-13 2006-03-13 Composizione ad uso cosmetico o dermatologico
PCT/IB2007/000598 WO2007105071A2 (en) 2006-03-13 2007-03-13 Composition for cosmetic or pharmaceutical-dermatological use

Publications (2)

Publication Number Publication Date
EP2004235A2 EP2004235A2 (en) 2008-12-24
EP2004235B1 true EP2004235B1 (en) 2010-03-24

Family

ID=38509847

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07733952A Active EP2004235B1 (en) 2006-03-13 2007-03-13 Composition for cosmetic or pharmaceutical-dermatological use

Country Status (10)

Country Link
US (1) US20090098226A1 (pl)
EP (1) EP2004235B1 (pl)
AT (1) ATE461691T1 (pl)
DE (1) DE602007005464D1 (pl)
DK (1) DK2004235T3 (pl)
ES (1) ES2342436T3 (pl)
IT (1) ITPD20060082A1 (pl)
PL (1) PL2004235T3 (pl)
PT (1) PT2004235E (pl)
WO (1) WO2007105071A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101205234B (zh) * 2007-12-14 2010-12-29 中山大学 姜黄素-锌化合物及其固体分散体的制备方法与应用
BR112012025488B1 (pt) * 2010-04-09 2020-12-29 Unilever N.V composição de cuidados orais e uso de uma fonte de íons de zinco
PH12013501964A1 (en) * 2011-04-04 2013-11-25 Unilever Ip Holdings B V Oral care compositions
GB201904469D0 (en) * 2019-03-29 2019-05-15 Givaudan Sa Cosmetic composition
CN114795995B (zh) * 2021-01-19 2025-12-16 株式会社爱茉莉太平洋 1,6-二磷酸果糖或其衍生物的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1170618B (it) * 1981-01-13 1987-06-03 Foscama Biomed Chim Farma Preparato farmacologico di frutto sio-1,6-difosfato ad azione terapeutica nei pazienti ustionati
US6051244A (en) * 1993-01-27 2000-04-18 Perricone; Nicholas V. Fructose diphosphate topical compositions
US20010051184A1 (en) * 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
US20030194446A1 (en) * 2002-04-10 2003-10-16 Akes Lindy K. Zinc oxide compositions for dermatheraputics
KR20040081248A (ko) * 2003-03-14 2004-09-21 (주)에코텍 울금추출물이 함유된 기능성 한방입욕제의 제조방법
US20080254152A1 (en) * 2003-12-18 2008-10-16 Karen Elizabeth Barrett Methods for Reducing the Effects of Stress on Skin Condition
US20060039887A1 (en) * 2004-08-20 2006-02-23 Infinity2 Health Sciences, Inc. Cosmetic or pharmaceutical composition for skin care

Also Published As

Publication number Publication date
ES2342436T3 (es) 2010-07-06
PL2004235T3 (pl) 2010-08-31
ITPD20060082A1 (it) 2007-09-14
ATE461691T1 (de) 2010-04-15
PT2004235E (pt) 2010-06-11
DK2004235T3 (da) 2010-07-12
DE602007005464D1 (de) 2010-05-06
US20090098226A1 (en) 2009-04-16
WO2007105071A3 (en) 2008-04-10
EP2004235A2 (en) 2008-12-24
WO2007105071A2 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
EP0955995B1 (en) Use of complexes for the preparation of compositions for the treatment of sensitive skin, preparation process and hypoallergenic compositions
EP3288531B1 (en) Method of improving skin health and compositions therefor
KR101345735B1 (ko) 인삼열매 아위버섯 발효액을 함유하는 화장료 조성물
WO2005070436A1 (en) A composition containing ginsenoside f1 or compound k for skin external application
EP2004235B1 (en) Composition for cosmetic or pharmaceutical-dermatological use
JP2025517588A (ja) 抗老衰効果を有するマツタケエキス含有組成物およびその使用
KR101136742B1 (ko) 연산호류 추출물 및 그것의 용도
CN113693966B (zh) 一种美白淡斑亮采霜及其制备方法
JP2001131049A (ja) 皮膚外用剤
CN103494737A (zh) 一种以姜花作为抗衰老护肤因子的化妆品制剂及制备方法
JP2001342112A (ja) 皮膚外用剤
CN111329783B (zh) 一种即时提亮肤色的组合物及其应用
JPH03112912A (ja) 化粧料組成物
CN112675094A (zh) 一种植物提取物、修复组合物、护肤用品及其制备方法
CN119157764A (zh) 颜色稳定的美白组合物和皮肤美白产品
KR20210072966A (ko) 나노캡슐화된 센텔라 추출물과 칼라민을 포함하는 피부보습 또는 피부염증 개선용 나노캡슐 조성물
KR20150116504A (ko) 티트리 추출물 및 소금을 포함하는 화장료 조성물
CN117297999A (zh) 一种改善皮肤状态的组合物及其应用
JP7411196B2 (ja) Ｘｖｉｉ型コラーゲン維持強化剤
KR20180124443A (ko) 흰목이버섯 자실체 추출물을 포함하는 피부장벽강화용 화장료 조성물
US10786441B2 (en) Skin barrier repair and maintenance composition
JP2005170918A (ja) 皮膚外用剤
CN117398318B (zh) 一种含有酵母菌发酵溶胞产物滤液的组合物及其应用
JP2003095859A (ja) 色素沈着抑制物質とその製法および用途
KR102797742B1 (ko) 새섬매자기 추출물을 유효성분으로 포함하는 피부 개선용 화장료 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081010

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20090113

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMALAND S.A.

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/02 20060101ALI20090728BHEP

Ipc: A61K 31/70 20060101ALI20090728BHEP

Ipc: A61P 1/00 20060101ALI20090728BHEP

Ipc: A61K 9/00 20060101AFI20090728BHEP

Ipc: A61K 31/12 20060101ALI20090728BHEP

Ipc: A61K 8/00 20060101ALI20090728BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

DAX Request for extension of the european patent (deleted)
GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602007005464

Country of ref document: DE

Date of ref document: 20100506

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20100601

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: N&G PATENT SERVICES SA

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2342436

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20100401325

Country of ref document: GR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100324

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100324

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100324

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100324

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100324

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100324

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100724

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100624

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20101228

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E009501

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: SCHARPER THERAPEUTICS S.R.L.

Free format text: PHARMALAND S.A.#XXVIII LUGLIO 218#BORGO MAGGIORE (SM) -TRANSFER TO- SCHARPER THERAPEUTICS S.R.L.#VIA MILANESE, 20#SESTO SAN GIOVANNI (MILANO) (IT)

REG Reference to a national code

Ref country code: NL

Ref legal event code: SD

Effective date: 20111221

Ref country code: NL

Ref legal event code: TD

Effective date: 20111221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100324

BECH Be: change of holder

Owner name: SCHARPER THERAPEUTICS S.R.L.

Effective date: 20120118

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20120126 AND 20120201

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: PHARMALAND SPA

Effective date: 20120313

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: SCHARPER THERAPEUTICS SRL

Effective date: 20120314

REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Owner name: SCHARPER THERAPEUTICS, S.R.L., IT

Effective date: 20120325

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602007005464

Country of ref document: DE

Owner name: SCHARPER THERAPEUTICS S.R.L., IT

Free format text: FORMER OWNER: PHARMALAND S.A., BORGO MAGGIORE, SM

Effective date: 20120322

Ref country code: DE

Ref legal event code: R082

Ref document number: 602007005464

Country of ref document: DE

Representative=s name: KOEPE & PARTNER, DE

Effective date: 20120322

Ref country code: DE

Ref legal event code: R082

Ref document number: 602007005464

Country of ref document: DE

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, DE

Effective date: 20120322

Ref country code: DE

Ref legal event code: R081

Ref document number: 602007005464

Country of ref document: DE

Owner name: SPECIALIST S.R.L., IT

Free format text: FORMER OWNER: PHARMALAND S.A., BORGO MAGGIORE, SM

Effective date: 20120322

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20100401325

Country of ref document: GR

Effective date: 20120403

REG Reference to a national code

Ref country code: GR

Ref legal event code: MF

Ref document number: 20100401325

Country of ref document: GR

Effective date: 20120508

REG Reference to a national code

Ref country code: HU

Ref legal event code: GB9C

Owner name: SCHARPER THERAPEUTICS S.R.L., IT

Free format text: FORMER OWNER(S): PHARMALAND S.A., SM

Ref country code: HU

Ref legal event code: FH1C

Free format text: FORMER REPRESENTATIVE(S): FRANKNE DR. MACHYTKA DAISY, GOEDOELLE, KEKES, MESZAROS & SZABO SZABADALMI ES VEDJEGY IRODA, HU

Representative=s name: GOEDOELLE, KEKES, MESZAROS & SZABO SZABADALMI , HU

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 461691

Country of ref document: AT

Kind code of ref document: T

Owner name: SCHARPER THERAPEUTICS S.R.L., IT

Effective date: 20121017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110313

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100324

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: SPECIALIST S.R.L., IT

Free format text: FORMER OWNER: SCHARPER THERAPEUTICS S.R.L., IT

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602007005464

Country of ref document: DE

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602007005464

Country of ref document: DE

Owner name: SPECIALIST S.R.L., IT

Free format text: FORMER OWNER: SCHARPER THERAPEUTICS S.R.L., SAN GIOVANNI, IT

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20151001 AND 20151007

REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Owner name: SPECIALIST S.R.L., IT

Effective date: 20151110

REG Reference to a national code

Ref country code: HU

Ref legal event code: GB9C

Owner name: SPECIALIST S.R.L., IT

Free format text: FORMER OWNER(S): PHARMALAND S.A., SM; SCHARPER THERAPEUTICS S.R.L., IT

Ref country code: HU

Ref legal event code: FH1C

Free format text: FORMER REPRESENTATIVE(S): GOEDOELLE, KEKES, MESZAROS & SZABO SZABADALMI ES VEDJEGY IRODA, HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: SPECIALIST S.R.L.; IT

Free format text: DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), OVERDRACHT; FORMER OWNER NAME: SCHARPER THERAPEUTICS S.R.L.

Effective date: 20151002

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: SPECIALIST S.R.L.

Effective date: 20160129

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: SPECIALIST S.R.L., IT

Effective date: 20160118

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 461691

Country of ref document: AT

Kind code of ref document: T

Owner name: SPECIALIST S.R.L., IT

Effective date: 20170329

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602007005464

Country of ref document: DE

Owner name: SCHARPER S.P.A., IT

Free format text: FORMER OWNER: SPECIALIST S.R.L., MILANO, IT

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20211111 AND 20211117

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: SCHARPER S.P.A.; IT

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE; FORMER OWNER NAME: SPECIALIST S.R.L.

Effective date: 20211124

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: SCHARPER S.P.A.; IT

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE; FORMER OWNER NAME: SPECIALIST S.R.L.

Effective date: 20211123

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 461691

Country of ref document: AT

Kind code of ref document: T

Owner name: SCHARPER S.P.A., IT

Effective date: 20220119

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: SCHARPER S.P.A.

Effective date: 20230417

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240222

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240319

Year of fee payment: 18

Ref country code: IE

Payment date: 20240222

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240402

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20240226

Year of fee payment: 18

Ref country code: DE

Payment date: 20240327

Year of fee payment: 18

Ref country code: CZ

Payment date: 20240223

Year of fee payment: 18

Ref country code: GB

Payment date: 20240322

Year of fee payment: 18

Ref country code: PT

Payment date: 20240308

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240226

Year of fee payment: 18

Ref country code: SE

Payment date: 20240229

Year of fee payment: 18

Ref country code: PL

Payment date: 20240223

Year of fee payment: 18

Ref country code: FR

Payment date: 20240226

Year of fee payment: 18

Ref country code: DK

Payment date: 20240318

Year of fee payment: 18

Ref country code: BE

Payment date: 20240226

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240401

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240401

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20250303

Year of fee payment: 19

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007005464

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250915

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250313

REG Reference to a national code

Ref country code: CH

Ref legal event code: H13

Free format text: ST27 STATUS EVENT CODE: U-0-0-H10-H13 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251023

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20250331

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20250401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250314

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 461691

Country of ref document: AT

Kind code of ref document: T

Effective date: 20250313

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20250313

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20250331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250401